Developer docs
API playgroundTry for free, no card

Search company profiles

Bluejay Diagnostics

Full company profile

uuid00000xr

Namestring
Bluejay Diagnostics
Legal namestring
Bluejay Diagnostics, Inc.
Websiteurl
bluejaydx.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Bluejay Diagnostics is a pre-revenue, clinical-stage medical diagnostics company developing the Symphony platform, a near-patient biomarker detection system designed to deliver quantitative clinical chemistry results in approximately 20 minutes from three drops of whole blood. The platform combines interrupted microfluidics, nanotechnology, and fluorescence enzyme immunoassay (FEIA/ELISA) methodology into a portable 16kg analyzer paired with single-use cartridges that contain all reagents and process samples without pre-processing or technician intervention. The lead product candidate, the Symphony IL-6 Test, targets sepsis triage and monitoring in critical care settings such as ICUs, emergency rooms, and LTACs, where rapid IL-6 biomarker quantification can guide time-sensitive treatment decisions.

The underlying detection technology is built on an exclusive global license (excluding Japan) from Toray Industries, supplemented by dual manufacturing partnerships with SanyoSeiko (Japan, announced October 2025) and Argonaut Manufacturing Services (United States, announced June 2026). The company has completed the SYMON-I study (results suggesting IL-6 may predict mortality in sepsis patients) and enrolled 624 patients in the SYMON-II pivotal trial toward an FDA De Novo submission. Additional pipeline assets include ALLEREYE for allergic conjunctivitis and stated future expansion potential into oncology and cardio-metabolic disease monitoring.

Bluejay is publicly traded on NASDAQ under ticker BJDX and has raised approximately $30M+ across eight equity and warrant-inducement financings between 2023 and June 2026, with most recent rounds led by H.C. Wainwright, Rodman and Renshaw, and Aegis Capital. The company reported a $6.85M net loss for FY2025 with cash of approximately $5.2M entering 2026, management has stated the existing runway extends only through approximately Q3 2026, and an additional ~$20M is required through fiscal year 2027. The business model is intended to revolve around sale of proprietary single-use test cartridges (consumables) and Symphony Analyzer hardware to hospitals and clinics via a direct sales motion upon FDA authorization, supported by collaborations such as the Blood Centers of America agreement signed February 2023. As of June 2026, the company had a market capitalization of approximately $2.25M and had executed a 1-for-4 reverse stock split in January 2026.

Short descriptiontext

Bluejay Diagnostics is a pre-revenue, clinical-stage diagnostics company developing the Symphony platform, a portable near-patient system for rapid IL-6 biomarker testing intended to triage sepsis patients in ICUs, emergency rooms, and LTACs pending FDA De Novo clearance.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersActon, United States
HQ citystring
Acton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
point-of-care diagnostics, biomarker detection platform, sepsis triage testing, near-patient immunoassay, rapid clinical chemistry
Industry3 codes
PRIMARYHLAHAAAL
Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Point-of-Care Diagnostic Testing
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Symphony IL-6 Test (when commercialized)
TypeHardware Sales
Description

Pre-revenue company developing rapid diagnostic platform. Revenue model will likely involve sale of proprietary test cartridges (consumables) and potentially the Symphony Analyzer hardware. Company is in clinical development stage pursuing FDA De Novo/510(k) clearance before commercialization.

bluejaydx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details1 tier
1No public pricing available
ModelOtherBilling cadencePay-as-you-go
Notes

Product not yet commercialized. No pricing details disclosed in available source materials.

bluejaydx.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Symphony
Description

Near-patient biomarker detection platform for rapid diagnostic testing in critical care settings, providing quantitative clinical chemistry results for triage and acute care situations.

bluejaydx.com
+2 more records
Core offering1 text field

Bluejay Diagnostics develops the Symphony platform, a near-patient biomarker detection system that combines fluorescence enzyme immunoassay (FEIA) methodology with microfluidics, nanotechnology, and interrupted fluid dynamics to deliver quantitative clinical chemistry results in approximately 20 minutes from whole blood. The platform consists of a portable Symphony Analyzer paired with single-use Symphony Cartridges containing all reagents; the lead product candidate is the Symphony IL-6 Test intended for sepsis triage and monitoring in critical care settings, with a pipeline that previously included the ALLEREYE test for allergic conjunctivitis. Products are currently labeled 'For Research Use Only' and are not yet FDA cleared or commercialized.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • IL-6 biomarker detection in ~20 minutes (vs. traditional lab turnaround times)
+3 more records
Product overview1 text field

Bluejay Diagnostics offers the Symphony™ platform, a near-patient biomarker detection system for critical care diagnostics. The platform consists of the Symphony Analyzer (portable fluorescence immuno-analyzer hardware) and Symphony Cartridges (single-use test devices with integrated reagents). The lead product candidate is the Symphony IL-6 Test for sepsis triage and monitoring, which uses interleukin-6 as a biomarker. Additional products include ALLEREYE™ for allergic conjunctivitis. The system provides laboratory-quality quantitative results in approximately 20 minutes using only three drops of whole blood, eliminating the need for specialized laboratory technicians or additional equipment.

Product and service5 records
1Symphony Platform
CategoryPoint-of-Care Diagnostic Platform
Description

A near-patient biomarker detection platform that combines fluorescence enzyme immunoassay (FEIA) methodology with microfluidics, nanotechnology, and interrupted fluid dynamics to deliver quantitative clinical chemistry results in approximately 20 minutes from whole blood. The system consists of a portable Symphony Analyzer and single-use Symphony Cartridges with integrated reagents, intended for hospitals, ICUs, emergency rooms, LTACs, and clinics performing triage and acute care diagnostics.

2Symphony IL-6 Test
CategoryDiagnostic Test Cartridge (Sepsis Triage)
Description

Rapid interleukin-6 (IL-6) biomarker test cartridge designed for sepsis triage and monitoring in critical care settings. Uses three drops of whole blood and delivers quantitative results in approximately 20 minutes via the Symphony Analyzer. Targeted at ICUs, emergency rooms, and acute care facilities where timely sepsis diagnosis informs treatment decisions.

3ALLEREYE
CategoryDiagnostic Test Cartridge (Ophthalmology)
Description

Point-of-care diagnostic test for allergic conjunctivitis on the Symphony platform.

4Symphony Analyzer
CategoryDiagnostic Analyzer Hardware
Description

Portable fluorescence immuno-analyzer that accepts Symphony Cartridges, designed for near-patient testing without requiring specialized laboratory technicians. Includes factory calibration (electronic, mechanical, thermal), onboard thermal printer, and optional barcode reader. Supports multiplexing of up to six samples or biomarkers.

5Symphony Cartridges
CategorySingle-Use Consumable Cartridges
Description

Single-use diagnostic test cartridges containing all required reagents, integrating whole blood processing, precision ELISA, and waste handling. Requires only three drops of whole blood with no pre-processing or additional reagents, enabling sample-to-result testing without technician intervention.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-06-02
Description

Strategic partnership to establish scalable U.S.-based manufacturing capabilities for Symphony platform. Collaboration aims to enhance supply chain resilience, reduce reliance on overseas manufacturing and import tariffs, and support future commercialization of IL-6 Test for sepsis and distribution across the United States.

2SanyoSeiko
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-10-09
Description

Expanded strategic partnership for manufacturing and commercialization of Symphony platform. SanyoSeiko provides comprehensive support including manufacturing, quality control, regulatory, and supply chain management. Builds on earlier partnership to support broader clinical validation and market introduction.

globenewswire.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-02-16
Description

Collaboration agreement to develop commercial relationships to serve unmet needs by utilizing the Symphony platform in the blood and hospital markets.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-12-08
Description

Collaboration agreement for developing point-of-care diagnostic test to quantify IL-6 in whole blood. Toray licensed its technology and know-how to Bluejay. Bluejay received exclusive license (except Japan) for development, marketing and manufacturing globally. Technology enables IL-6 detection without pre-treatment.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cytovale's IntelliSep is a FDA-cleared rapid cellular biomarker test for sepsis triage in the ED — directly competing with Bluejay's Symphony IL-6 on the same customer (EDs/ICUs), same use case (sepsis triage), and same speed proposition (minutes vs. hours). The most directly comparable POC sepsis diagnostic peer.

TypeDirect peer
Description

T2 Biosystems develops T2Bacteria and T2Candida rapid direct-from-blood molecular diagnostics for sepsis, marketed to the same hospital customer base and competing on time-to-result vs. blood culture. Both target sepsis diagnostics at the same hospital labs/ICUs, though T2 uses molecular rather than immunoassay technology.

TypeEmerging player
Description

Inflammatix is developing HostDx, a host-response rapid test for acute infections and sepsis that uses immune-transcriptional signatures. Competes with Bluejay in sepsis triage at point-of-care and is similarly pre-commercial, making it a relevant emerging competitor for the same clinical and commercial audience.

TypeBroad incumbent
Description

QuidelOrtho's Triage family (e.g., Triage BNP, Triage MeterPro) is an established rapid POC immunoassay platform sold to hospitals and EDs. It competes with Symphony as a broad incumbent with installed instrumentation, sales force, and FDA-cleared menus, though it does not target IL-6 specifically.

5Abbott Point of Care
TypeBroad incumbent
Description

Abbott's i-STAT and Alinity ci-series are dominant POC clinical chemistry/immunoassay analyzers deployed across US hospitals, ICUs, and EDs. Represents the largest incumbent that Bluejay will compete with on hospital rapid diagnostic menus and connectivity infrastructure.

TypeBroad incumbent
Description

bioMérieux's VIDAS and mini-VIDAS are widely deployed immunoassay analyzers used for clinical chemistry and biomarker testing (including procalcitonin for sepsis) in hospitals. A large established incumbent in the same POC/central-lab immunoassay space Bluejay targets.

TypeBroad incumbent
Description

Siemens' epoc blood analysis system and Atellica clinical chemistry/immunoassay platform serve hospitals and ICUs with rapid POC and central-lab testing. A broad incumbent POC diagnostics competitor with established sales channels and integration with hospital IT.

TypeBroad incumbent
Description

Roche's cobas family of clinical chemistry and immunoassay analyzers is a market-leading central-lab platform, and Roche also has POC presence. While Bluejay competes on speed and footprint rather than menu breadth, Roche represents the dominant incumbent whose installed base Bluejay would seek to displace at the ED/ICU POC.

TypeEmerging player
Description

EKF Diagnostics develops and sells POC clinical chemistry and biomarker analyzers (e.g., QuikRead, DiaSpect) primarily to smaller hospitals, clinics, and emerging markets — directly overlapping with Bluejay's stated target of LTACs, smaller hospitals, and clinics that have been priced out of central-lab platforms.

TypeOthers
Description

Mesa Labs (now part of Mettler-Toledo's related IVD QC business) manufactures IVD quality controls, calibrators, and proficiency testing materials used by clinical labs and IVD manufacturers. Comparable not as a competitor but as a supplier/ecosystem participant in the IVD consumables value chain Bluejay operates in.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bluejay Diagnostics

Point-of-Care Diagnostic Testingbluejaydx.com

Bluejay Diagnostics is a pre-revenue, clinical-stage diagnostics company developing the Symphony platform, a portable near-patient system for rapid IL-6 biomarker testing intended to triage sepsis patients in ICUs, emergency rooms, and LTACs pending FDA De Novo clearance.

What Bluejay Diagnostics does

Bluejay Diagnostics is a pre-revenue, clinical-stage medical diagnostics company developing the Symphony platform, a near-patient biomarker detection system designed to deliver quantitative clinical chemistry results in approximately 20 minutes from three drops of whole blood. The platform combines interrupted microfluidics, nanotechnology, and fluorescence enzyme immunoassay (FEIA/ELISA) methodology into a portable 16kg analyzer paired with single-use cartridges that contain all reagents and process samples without pre-processing or technician intervention. The lead product candidate, the Symphony IL-6 Test, targets sepsis triage and monitoring in critical care settings such as ICUs, emergency rooms, and LTACs, where rapid IL-6 biomarker quantification can guide time-sensitive treatment decisions.

The underlying detection technology is built on an exclusive global license (excluding Japan) from Toray Industries, supplemented by dual manufacturing partnerships with SanyoSeiko (Japan, announced October 2025) and Argonaut Manufacturing Services (United States, announced June 2026). The company has completed the SYMON-I study (results suggesting IL-6 may predict mortality in sepsis patients) and enrolled 624 patients in the SYMON-II pivotal trial toward an FDA De Novo submission. Additional pipeline assets include ALLEREYE for allergic conjunctivitis and stated future expansion potential into oncology and cardio-metabolic disease monitoring.

Bluejay is publicly traded on NASDAQ under ticker BJDX and has raised approximately $30M+ across eight equity and warrant-inducement financings between 2023 and June 2026, with most recent rounds led by H.C. Wainwright, Rodman and Renshaw, and Aegis Capital. The company reported a $6.85M net loss for FY2025 with cash of approximately $5.2M entering 2026, management has stated the existing runway extends only through approximately Q3 2026, and an additional ~$20M is required through fiscal year 2027. The business model is intended to revolve around sale of proprietary single-use test cartridges (consumables) and Symphony Analyzer hardware to hospitals and clinics via a direct sales motion upon FDA authorization, supported by collaborations such as the Blood Centers of America agreement signed February 2023. As of June 2026, the company had a market capitalization of approximately $2.25M and had executed a 1-for-4 reverse stock split in January 2026.

Bluejay Diagnostics firmographics

Firmographics
Name
Bluejay Diagnostics
Legal name
Bluejay Diagnostics, Inc.
Website
https://bluejaydx.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Bluejay Diagnostics is a pre-revenue, clinical-stage diagnostics company developing the Symphony platform, a portable near-patient system for rapid IL-6 biomarker testing intended to triage sepsis patients in ICUs, emergency rooms, and LTACs pending FDA De Novo clearance.
Ownership category
akta.pro rank

Bluejay Diagnostics industry classification

Industry
Product category
Point-of-Care Diagnostic Testing
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAAAL
Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Point-of-care diagnostics
  • Biomarker detection platform
  • Sepsis triage testing
  • Near-patient immunoassay
  • Rapid clinical chemistry

Where Bluejay Diagnostics is headquartered

Location

Headquarters

HQ city
Acton
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Bluejay Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Symphony IL-6 Test (when commercialized): Pre-revenue company developing rapid diagnostic platform. Revenue model will likely involve sale of proprietary test cartridges (consumables) and potentially the Symphony Analyzer hardware. Company is in clinical development stage pursuing FDA De Novo/510(k) clearance before commercialization.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goNo public pricing available

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Bluejay Diagnostics product offering

Product offering

Core offering

Bluejay Diagnostics develops the Symphony platform, a near-patient biomarker detection system that combines fluorescence enzyme immunoassay (FEIA) methodology with microfluidics, nanotechnology, and interrupted fluid dynamics to deliver quantitative clinical chemistry results in approximately 20 minutes from whole blood. The platform consists of a portable Symphony Analyzer paired with single-use Symphony Cartridges containing all reagents; the lead product candidate is the Symphony IL-6 Test intended for sepsis triage and monitoring in critical care settings, with a pipeline that previously included the ALLEREYE test for allergic conjunctivitis. Products are currently labeled 'For Research Use Only' and are not yet FDA cleared or commercialized.

Product overview

Bluejay Diagnostics offers the Symphony™ platform, a near-patient biomarker detection system for critical care diagnostics. The platform consists of the Symphony Analyzer (portable fluorescence immuno-analyzer hardware) and Symphony Cartridges (single-use test devices with integrated reagents). The lead product candidate is the Symphony IL-6 Test for sepsis triage and monitoring, which uses interleukin-6 as a biomarker. Additional products include ALLEREYE™ for allergic conjunctivitis. The system provides laboratory-quality quantitative results in approximately 20 minutes using only three drops of whole blood, eliminating the need for specialized laboratory technicians or additional equipment.

Differentiator

Problem solved

Functional benefit

Brands

  • Symphony: Near-patient biomarker detection platform for rapid diagnostic testing in critical care settings, providing quantitative clinical chemistry results for triage and acute care situations.
  • Symphony IL-6 Test
  • Allereye

Products and services

  • Symphony Platform A near-patient biomarker detection platform that combines fluorescence enzyme immunoassay (FEIA) methodology with microfluidics, nanotechnology, and interrupted fluid dynamics to deliver quantitative clinical chemistry results in approximately 20 minutes from whole blood. The system consists of a portable Symphony Analyzer and single-use Symphony Cartridges with integrated reagents, intended for hospitals, ICUs, emergency rooms, LTACs, and clinics performing triage and acute care diagnostics.
  • Symphony IL-6 Test Rapid interleukin-6 (IL-6) biomarker test cartridge designed for sepsis triage and monitoring in critical care settings. Uses three drops of whole blood and delivers quantitative results in approximately 20 minutes via the Symphony Analyzer. Targeted at ICUs, emergency rooms, and acute care facilities where timely sepsis diagnosis informs treatment decisions.
  • ALLEREYE Point-of-care diagnostic test for allergic conjunctivitis on the Symphony platform.
  • Symphony Analyzer Portable fluorescence immuno-analyzer that accepts Symphony Cartridges, designed for near-patient testing without requiring specialized laboratory technicians. Includes factory calibration (electronic, mechanical, thermal), onboard thermal printer, and optional barcode reader. Supports multiplexing of up to six samples or biomarkers.
  • Symphony Cartridges Single-use diagnostic test cartridges containing all required reagents, integrating whole blood processing, precision ELISA, and waste handling. Requires only three drops of whole blood with no pre-processing or additional reagents, enabling sample-to-result testing without technician intervention.

Quantifiable outcome

  • IL-6 biomarker detection in ~20 minutes (vs. traditional lab turnaround times)
  • +3 more outcomes

Companies that use Bluejay Diagnostics

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Bluejay Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Bluejay Diagnostics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Argonaut Manufacturing ServicescoreOEM/ Whitelabel/ Licensing Partner · 2 June 2026Strategic partnership to establish scalable U.S.-based manufacturing capabilities for Symphony platform. Collaboration aims to enhance supply chain resilience, reduce reliance on overseas manufacturing and import tariffs, and support future commercialization of IL-6 Test for sepsis and distribution across the United States.
  • SanyoSeikocoreOEM/ Whitelabel/ Licensing Partner · 9 October 2025Expanded strategic partnership for manufacturing and commercialization of Symphony platform. SanyoSeiko provides comprehensive support including manufacturing, quality control, regulatory, and supply chain management. Builds on earlier partnership to support broader clinical validation and market introduction.
  • Blood Centers of AmericaminorStrategic or Co-development Partner · 16 February 2023Collaboration agreement to develop commercial relationships to serve unmet needs by utilizing the Symphony platform in the blood and hospital markets.
  • Toray Industries, Inc.coreTechnology or Integration · 8 December 2020Collaboration agreement for developing point-of-care diagnostic test to quantify IL-6 in whole blood. Toray licensed its technology and know-how to Bluejay. Bluejay received exclusive license (except Japan) for development, marketing and manufacturing globally. Technology enables IL-6 detection without pre-treatment.

Scale indicators14 records

Recent moves4 records

Expansion highlights6 records

Bluejay Diagnostics competitors and assessment

Company assessment

Direct peers

  • Cytovale: Cytovale's IntelliSep is a FDA-cleared rapid cellular biomarker test for sepsis triage in the ED — directly competing with Bluejay's Symphony IL-6 on the same customer (EDs/ICUs), same use case (sepsis triage), and same speed proposition (minutes vs. hours). The most directly comparable POC sepsis diagnostic peer.
  • T2 Biosystems: T2 Biosystems develops T2Bacteria and T2Candida rapid direct-from-blood molecular diagnostics for sepsis, marketed to the same hospital customer base and competing on time-to-result vs. blood culture. Both target sepsis diagnostics at the same hospital labs/ICUs, though T2 uses molecular rather than immunoassay technology.

Emerging players

  • Inflammatix: Inflammatix is developing HostDx, a host-response rapid test for acute infections and sepsis that uses immune-transcriptional signatures. Competes with Bluejay in sepsis triage at point-of-care and is similarly pre-commercial, making it a relevant emerging competitor for the same clinical and commercial audience.
  • EKF Diagnostics: EKF Diagnostics develops and sells POC clinical chemistry and biomarker analyzers (e.g., QuikRead, DiaSpect) primarily to smaller hospitals, clinics, and emerging markets — directly overlapping with Bluejay's stated target of LTACs, smaller hospitals, and clinics that have been priced out of central-lab platforms.

Broad incumbents

  • QuidelOrtho: QuidelOrtho's Triage family (e.g., Triage BNP, Triage MeterPro) is an established rapid POC immunoassay platform sold to hospitals and EDs. It competes with Symphony as a broad incumbent with installed instrumentation, sales force, and FDA-cleared menus, though it does not target IL-6 specifically.
  • Abbott Point of Care: Abbott's i-STAT and Alinity ci-series are dominant POC clinical chemistry/immunoassay analyzers deployed across US hospitals, ICUs, and EDs. Represents the largest incumbent that Bluejay will compete with on hospital rapid diagnostic menus and connectivity infrastructure.
  • bioMérieux: bioMérieux's VIDAS and mini-VIDAS are widely deployed immunoassay analyzers used for clinical chemistry and biomarker testing (including procalcitonin for sepsis) in hospitals. A large established incumbent in the same POC/central-lab immunoassay space Bluejay targets.
  • Siemens Healthineers: Siemens' epoc blood analysis system and Atellica clinical chemistry/immunoassay platform serve hospitals and ICUs with rapid POC and central-lab testing. A broad incumbent POC diagnostics competitor with established sales channels and integration with hospital IT.
  • Roche Diagnostics: Roche's cobas family of clinical chemistry and immunoassay analyzers is a market-leading central-lab platform, and Roche also has POC presence. While Bluejay competes on speed and footprint rather than menu breadth, Roche represents the dominant incumbent whose installed base Bluejay would seek to displace at the ED/ICU POC.

Others

  • Mesa Labs: Mesa Labs (now part of Mettler-Toledo's related IVD QC business) manufactures IVD quality controls, calibrators, and proficiency testing materials used by clinical labs and IVD manufacturers. Comparable not as a competitor but as a supplier/ecosystem participant in the IVD consumables value chain Bluejay operates in.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks1 record

Key highlights6 records

Customer concentration

Bluejay Diagnostics social profiles

Digital presence

Bluejay Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bluejay Diagnostics leadership team

Management profile

Number of profiles

Profiles12 records

Bluejay Diagnostics funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bluejay Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bluejay Diagnostics

What does Bluejay Diagnostics do?

Bluejay Diagnostics develops the Symphony platform, a near-patient biomarker detection system that combines fluorescence enzyme immunoassay (FEIA) methodology with microfluidics, nanotechnology, and interrupted fluid dynamics to deliver quantitative clinical chemistry results in approximately 20 minutes from whole blood. The platform consists of a portable Symphony Analyzer paired with single-use Symphony Cartridges containing all reagents; the lead product candidate is the Symphony IL-6 Test intended for sepsis triage and monitoring in critical care settings, with a pipeline that previously included the ALLEREYE test for allergic conjunctivitis. Products are currently labeled 'For Research Use Only' and are not yet FDA cleared or commercialized.

Is Bluejay Diagnostics a public or private company?

Bluejay Diagnostics is a public company. It is classified as public and is currently operating.

When was Bluejay Diagnostics founded?

Bluejay Diagnostics was founded in 2015. It employs 11 to 50 people.

Where is Bluejay Diagnostics based?

Bluejay Diagnostics is headquartered in Acton, United States, in the North America region.

How does Bluejay Diagnostics make money?

One revenue line is on record: symphony IL-6 Test (when commercialized).

Who are Bluejay Diagnostics's main competitors?

Direct peers on record are Cytovale and T2 Biosystems. Emerging players are Inflammatix and EKF Diagnostics. Broad incumbents are QuidelOrtho, Abbott Point of Care, bioMérieux, Siemens Healthineers and Roche Diagnostics. Mesa Labs is listed as an others.

Does Bluejay Diagnostics have an API?

No public API is recorded for Bluejay Diagnostics.

What industry is Bluejay Diagnostics in?

Bluejay Diagnostics's product category is Point-of-Care Diagnostic Testing. Its primary akta.pro industry code is HLAHAAAL, Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables), with a secondary code of HLAAALAF, Companion Diagnostics (CDx) & Therapy Selection Assays. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeBluejay Diagnostics Reports Q3 2026 Update and $7.38 Million Cash Balance | BJDX Stock NewsBluejay Diagnostics reported Q3 2026 progress on its Symphony IL-6 platform, completing enrollment in the SYMON-II study with 777 evaluable patients. The company holds $7.38 million in cash as of September 30, 2026, and targets an FDA 510(k) submission in the first half of 2027.Worcester Business JournalActon’s Bluejay Diagnostics reaches manufacturing milestone for sepsis testActon-based Bluejay Diagnostics has established manufacturing for its diagnostic cartridges at a partner’s facility in Japan, fulfilling a requirement under its license agreement with Toray Industries. The company is working toward FDA clearance for the Symphony IL-6 test, which measures inflammation markers to assess mortality risk in sepsis patients, while simultaneously scaling production capabilities in both Japan and the United States. Despite this milestone, the company faces ongoing financial challenges, having reported a net loss and indicating a need for additional funding through 2027 to support its commercialization plan.Stock TitanBluejay Diagnostics reports SYMON-II baseline dataBluejay Diagnostics announced baseline clinical data from its SYMON-II study, reporting 777 evaluable patients with 140 deaths at 28 days, an 18% mortality rate. The data show 84% bacterial infection and 56.4% septic shock among non-survivors. The company is continuing analysis to evaluate IL-6's prognostic performance.American Banking and Market NewsBluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest UpdateBluejay Diagnostics saw short interest fall 50.4% to 131,482 shares as of September 15th. Major shareholder Financial Lp Hrt bought 64,047 shares at $1.51, increasing its stake by 101.75%. Analysts rate the stock a consensus 'Sell'.Markets DailyBluejay Diagnostics, Inc. (NASDAQ:BJDX) Shares Shorted: Short Interest Down 50.4% in SeptemberBluejay Diagnostics' short interest fell 50.4% to 131,482 shares as of September 15th, down from 265,115 on August 31st. The stock traded down 9% to $0.85, while analysts hold a sell rating. The company reported a loss of $1.12 per share for the quarter.Ticker ReportBluejay Diagnostics (NASDAQ:BJDX) Rating Lowered to Sell at Wall Street ZenWall Street Zen downgraded Bluejay Diagnostics to a sell rating, and Weiss Ratings reiterated a sell (e+) rating. The stock opened at $0.85, and major shareholder Financial Lp Hrt sold 34,938 shares at $1.40. The company's average rating is now Sell.AdvfnBluejay Diagnostics Federal Healthcare Partnership Builds Commercial Pathway Ahead of FDA ClearanceBluejay Diagnostics partnered with Lovell Government Services to establish federal procurement infrastructure for its Symphony near-patient diagnostic platform. The agreement covers distribution and co-marketing for VA, DoD, and IHS, but Symphony remains investigational with no purchase commitments. FDA authorization via SYMON-II study is the key catalyst for commercialization.Markets DailyBluejay Diagnostics (NASDAQ:BJDX) Downgraded to Sell Rating by Wall Street ZenWall Street Zen downgraded Bluejay Diagnostics from a hold to a sell rating in a research note released Saturday, while Weiss Ratings reissued a sell (e+) rating on Wednesday, June 24th. The stock opened at $0.90 Friday, with a market cap of $4.02 million and a 12-month high of $16.68. Financial Lp Hrt sold 34,938 shares at $1.40, and Armistice Capital bought 65,000 shares in the fourth quarter.Quiver Quantitative$BJDX stock is up 11% today. Here's what we see in our data. | BJDX Stock NewsBJDX shares rose 11% in a day with roughly $9.73 million in trading volume, according to Polygon data reported by Quiver Quantitative. Insiders have made seven trades in six months, six purchases and one sale, while five institutional investors added shares and seven reduced positions in the most recent quarter.Markets DailyBluejay Diagnostics (NASDAQ:BJDX) Rating Increased to Hold at Wall Street ZenWall Street Zen upgraded its rating on Bluejay Diagnostics from a sell to a hold in a research note issued on Saturday. The company currently maintains a consensus 'Sell' rating, with Weiss Ratings also reiterating a 'sell (e+)' rating on Wednesday. Bluejay Diagnostics recently reported earnings per share of ($1.12), beating the consensus estimate significantly.